|
|
Post by cjc04 on Nov 11, 2015 16:48:24 GMT -5
I don't care what Elon Musk does. If he's literally confronting bashers on twitter, that's just dumb and immature... and only encourages more bashing. I would never invest in a company whose CEO was using part of his day to confront bashers on social media... amateur move. Like there's not enough hours in the day already? Exactly!!!! Bad example. Elon Musk is one of a kind, genius/crazy and I don't mean one or the other, he's both. A credible CEO isn't "tit for tatting" on social media or anywhere else. |
|
|
|
Post by seanismorris on Nov 11, 2015 17:07:27 GMT -5
Twitter is for twits. That is not a reliable forum for information.
What he needs to do is either give an interview with a reputable news source or give us a press release. He doesn't speak well, so I rather have Matt give an interview about how the Listing came about and their future intentions.
As an investor, I like the fact MannKind was able to raise money. But as someone watching the market, the Listing comes off as dishonorable. We need a lot more color and insight into the thought process.
During that interview, Matt needs to address the companies poor communication with investors and what they'll do to fix it. And by doing so, limit the disinformation of people like AF.
I give equal blame to MannKind and people like AF.
|
|
nsmyth
Lab Rat
Posts: 43 
Sentiment: Long
|
Post by nsmyth on Nov 11, 2015 17:34:22 GMT -5
I don't care what Elon Musk does. If he's literally confronting bashers on twitter, that's just dumb and immature... and only encourages more bashing. I would never invest in a company whose CEO was using part of his day to confront bashers on social media... amateur move. Like there's not enough hours in the day already? Exactly!!!! Bad example. Elon Musk is one of a kind, genius/crazy and I don't mean one or the other, he's both. A credible CEO isn't "tit for tatting" on social media or anywhere else. well the CEO of MNKD did compare the company to tesla on the conf call this week.. just saying... |
|
|
|
Post by u1682002 on Nov 11, 2015 17:41:51 GMT -5
Look, I know Hakan Edstrom. I worked directly for him. He does not put out press releases for the sole purposes of placating nervous investors. These are real executives running a real company. They don't issue constant press releases like a bunch of other penny stock scams, all for the purpose of (unsuccessfully) lifting their stock price. That tactic never works in the long run and this is a company with a very long term plan. The philosophy at Mannkind has always been to let the science speak for the company. The more people who get treated with Afrezza, the more the stock price will take care of itself. Some people think that only issuing press releases when absolutely necessary is a bad thing. I see it as a mature, responsible thing that doesn't lend itself to "hype" which is what many of you are craving for. If there are material, provable actions that people are doing to manipulate the stock, let the SEC take care of it... and that is exactly what MKND said they are letting them do. It's not MNKD's responsibility to address every nervous nellie or message board basher. Their time is better spent elsewhere.
I am not sure if your message is a direct response to my message. I normally do not respond to any message unless I have some good things to say. I decided to respond your message is because you claimed you directly worked for Hakan. I must say your mentality is exactly the reason why MNKD has such a good product but is in such bad financial situation.
I can live with your opinion but I have to disagree with you with all due respect. First of all, I was not nervous and, as a matter of fact, I treated this as a good opportunity to accumulate more cheap shares. I am outraged is because this time is not just normal timing. This will affect how much working capital MNKD will gain for the next 10 to 12 months. I think MNKD management definitely needs to respond and defend its stock right now. This attack actually provided a perfect opportunity for them to undone some of the damage from the latest the conference call. I agree with you science is the key. However, only having science is not nearly enough for a public traded company to survive otherwise we only need a CTO and why bother to have a CEO and CFO.
|
|
|
|
Post by jpg on Nov 11, 2015 23:39:17 GMT -5
Look, I know Hakan Edstrom. I worked directly for him. He does not put out press releases for the sole purposes of placating nervous investors. These are real executives running a real company. They don't issue constant press releases like a bunch of other penny stock scams, all for the purpose of (unsuccessfully) lifting their stock price. That tactic never works in the long run and this is a company with a very long term plan. The philosophy at Mannkind has always been to let the science speak for the company. The more people who get treated with Afrezza, the more the stock price will take care of itself. Some people think that only issuing press releases when absolutely necessary is a bad thing. I see it as a mature, responsible thing that doesn't lend itself to "hype" which is what many of you are craving for. If there are material, provable actions that people are doing to manipulate the stock, let the SEC take care of it... and that is exactly what MKND said they are letting them do. It's not MNKD's responsibility to address every nervous nellie or message board basher. Their time is better spent elsewhere. This press release was not to placate nervous investors but to assure the survival of Mannkind from a financing point of view. I have been a long time investor (over 8 years) but have gradually sold out all my shares over the last year or so. One misstep after the other. If what you are saying above is the thinking at Mannkind it scares me and explains to me the deeply flawed thinking that seems to afflict Mannkind management. The days leading up to a big refinancing (and crucially based on share price around that time) are very material and a strong denial or clarification would have been urgently needed. No wonder short find it so easy to punch around a company that plays by the rules it wants or thinks it should play by and not by the rules it has to play by. And if you answer the high road is a better strategy I would answer back: how has that worked out for us from a financing point of view? Always dilute at the absolute worst time and under dire conditions and at the mercy of crooks. Why didn't management dilute when we were at a 52 week high (like most well run biotech do)? Because it wouldn't have been popular? Guess who isn't very popular right now and for good reason... |
|
|
|
Post by lorcan458 on Nov 12, 2015 0:50:09 GMT -5
No wonder short find it so easy to punch around a company that plays by the rules it wants or thinks it should play by and not by the rules it has to play by. You are absolutely right. Imagine what the likes of Larry Ellison, Steve Jobs, Bill Gates or Mark Cuban would do in this situation. They would play to win. To dominate the market. Mannkind has the best mealtime insulin the world has ever seen. By a large margin. You think any of those 4 wouldn't get that word out through every means available, regardless of Sanofi's official marketing effort? Do you think they wouldn't privately or, if necessary, publicly, make it clear that Sanofi has already lost a lawsuit for sandbagging a smaller partner for their own strategic benefit to the detriment of their partner. I have not sold a single share and if you see my post history, you'll see I'm very bullish on the long term prospects. The one thing that really gets me angry is the passivity. The words they use on conference calls, the tone of voice, the absolutely unnecessary equivocations appended to what should be a YES or NO answer. If you want to be a CEO, you have to be at the vanguard of those fighting to make sure the very best of what your company has to offer is known and understood in the marketplace. |
|
|
|
Post by mbseeking on Nov 12, 2015 1:04:33 GMT -5
I feel I've been misreading Hakan. The inflection point was this conference call.
Cultures are different. The US is one that ascribes a lot to what a person says, and how they say it. A lot cultures value that much less, and look more at the unspoken.
Consequently I miscued on Hakan.
I believe he entered into a good faith agreement with the Chris Viehbacher - Sanofi. That company (then) and his belief in Afrezza led him to believe the product would sail off the shelves. How can an honest CEO dilute capital then , when that is what he believes?
Meantime the greedy , evil hedge funds kept shorting MNKD out of the capital market. Time passed.
Brandicourt replaced Viehbacher and the rules changed over night. Such things are never said they have to be figured out. Hakan may have got an inkling earlier in his meetings , but SNY only just confirmed their lethargy at their recent public meetings. You cant blame Hakan for this. And you cant expect a young , innovative drug company straining its every resource to bring a most amazing thing to market to have backup plan after backup plan in place.
Brandicourt SNY were not sandbagging, they were stonewalling. They knew MNKDs financing were both legitimately declining and under hedge fund short attack.
What can David do with this Goliath ? Oh yeah, its biblical. He finds a slingshot. Al calls in a favour in Israel. No shame in that. ( but look at how much the Israelis are bitching, regulators threatening etc ..this is no Jewish lovefest)
Two birds with one stone. Non shortable fresh capital, and now MNKD can survive.
Why is that important? The performance pendulum on the MNKD / SNY relationship has been swinging toward SNY. Milestone payments are now sales and development (trial) related (SNY) , rather than production (MNKD). The biggest, and most expensive has yet to be cranked up - by SNY. This is the world as we understood it at the time of SNY Meet the Manager meeting. SNY declared.. "haha, we got you and are doing nothing , spending no more money , you're gunna die and will take your IP"
Well quite simply Hakan and Matt not only just turned the tables they spun them. SNY has to accelerate immensely to get back to a reasonable spot , or legitimately , MNKD can go to someone else. Seriously , if SNY dont so something do you not think by 2Q16 SNY is dumped (within terms of contract) and TEVA signed up , or something equally gutsy?
I absolutely believe this is the negotiating position and dont fear it at all. In fact, bring it on. Mannkind just told SNY to Sh_t or get off the pot. I can even imagine Hakan saying that to Brandicourt , all the time perfectly composed.
So no we dont get a lot of perfect American English oratory from Hakan. We dont get raised voices or even anger. We just get steely resolve at the conference table.
I'm so impressed.. I wish I could buy a lot more of this stock. This is why Al is keeping Hakan and Matt.
|
|
|
|
Post by trenddiver on Nov 12, 2015 1:10:44 GMT -5
Look, I know Hakan Edstrom. I worked directly for him. He does not put out press releases for the sole purposes of placating nervous investors. These are real executives running a real company. They don't issue constant press releases like a bunch of other penny stock scams, all for the purpose of (unsuccessfully) lifting their stock price. That tactic never works in the long run and this is a company with a very long term plan. The philosophy at Mannkind has always been to let the science speak for the company. The more people who get treated with Afrezza, the more the stock price will take care of itself. Some people think that only issuing press releases when absolutely necessary is a bad thing. I see it as a mature, responsible thing that doesn't lend itself to "hype" which is what many of you are craving for. If there are material, provable actions that people are doing to manipulate the stock, let the SEC take care of it... and that is exactly what MKND said they are letting them do. It's not MNKD's responsibility to address every nervous nellie or message board basher. Their time is better spent elsewhere. This press release was not to placate nervous investors but to assure the survival of Mannkind from a financing point of view. I have been a long time investor (over 8 years) but have gradually sold out all my shares over the last year or so. One misstep after the other. If what you are saying above is the thinking at Mannkind it scares me and explains to me the deeply flawed thinking that seems to afflict Mannkind management. The days leading up to a big refinancing (and crucially based on share price around that time) are very material and a strong denial or clarification would have been urgently needed. No wonder short find it so easy to punch around a company that plays by the rules it wants or thinks it should play by and not by the rules it has to play by. And if you answer the high road is a better strategy I would answer back: how has that worked out for us from a financing point of view? Always dilute at the absolute worst time and under dire conditions and at the mercy of crooks. Why didn't management dilute when we were at a 52 week high (like most well run biotech do)? Because it wouldn't have been popular? Guess who isn't very popular right now and for good reason... This is why I have no respect for management, especially Matt. In the summer of 2014, when the SP was $8-$10 Mannkind could have and should have sold the same 50,000,000 shares and raised $400m-$500m. Mannkind would have then had plenty of cash to pay off all of the debt, finance its TS R&D, and provide sufficient cash flow to finance at least 3 years of cash flow. They also would have been in a much stronger possession to be able to negotiate a better deal with Sanofi or some other BP candidate. But what did our management do? They SOLD THEIR OWN SHARES, leaving us as the bag holders. Trend |
|
|
|
Post by silentknight on Nov 12, 2015 1:15:51 GMT -5
No wonder short find it so easy to punch around a company that plays by the rules it wants or thinks it should play by and not by the rules it has to play by. You are absolutely right. Imagine what the likes of Larry Ellison, Steve Jobs, Bill Gates or Mark Cuban would do in this situation. They would play to win. To dominate the market. Mannkind has the best mealtime insulin the world has ever seen. By a large margin. You think any of those 4 wouldn't get that word out through every means available, regardless of Sanofi's official marketing effort? Do you think they wouldn't privately or, if necessary, publicly, make it clear that Sanofi has already lost a lawsuit for sandbagging a smaller partner for their own strategic benefit to the detriment of their partner. I have not sold a single share and if you see my post history, you'll see I'm very bullish on the long term prospects. The one thing that really gets me angry is the passivity. The words they use on conference calls, the tone of voice, the absolutely unnecessary equivocations appended to what should be a YES or NO answer. If you want to be a CEO, you have to be at the vanguard of those fighting to make sure the very best of what your company has to offer is known and understood in the marketplace. You're right but neither Hakan nor Matt has done much in the past year to inspire much investor confidence or publicly raise awareness for their product. To the contrary, many of their comments seem to have done more harm than good. Your points regarding Ellison, Jobs, Gates, and Cuban are good examples of company leaders who LEAD and undertake great effort to ensure their product and company succeeds. The characteristics of leadership they all exhibit are notable and they fight to ensure success, openly if required. MNKD leadership might want to let the science speak for itself, but while the science is undeniable and the product is effective, I'd prefer to have someone at the helm that knows less about the science and more about the business. Hakan doesn't strike me as strong in either. |
|
|
|
Post by dreamboatcruise on Nov 12, 2015 1:24:25 GMT -5
mbseeking... I think your imagining some monumental battle between SNY and MNKD, but if your wild idea is correct about the battle, I doubt this financing would change anything.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Nov 12, 2015 1:33:35 GMT -5
Agree MBS! The TASE move was brilliant; done swiftly too; in a low-key, under-the-radar, movement; kinda like a Beethoven sonata violin piece. Meanwhile today, the attempt to undermine the TASE deal by the spreading of a false rumor, bordering on fraud, fell apart. And, the MNKD press release today, right after the closing bell, was a simple, matter-of-fact, reaffirmation of the TASE deal, and that was it. Again, brilliant move on MNKD's part; by focusing strictly on the TASE deal itself; taking the high road, and staying away from any of that pond scum that occurred earlier in the day. Aloha.
|
|
|
|
Post by mbseeking on Nov 12, 2015 1:34:55 GMT -5
I believe every business negotiation is backstopped by either party retaining a position to walk away. MNKD just reinstated its ability to do that.
|
|
|
|
Post by trenddiver on Nov 12, 2015 1:45:02 GMT -5
I believe every business negotiation is backstopped by either party retaining a position to walk away. MNKD just reinstated its ability to do that. And how is Mannkind supposed to just walk away? It's Sanofi that has the right to terminate the agreement, not Mannkind. |
|
|
|
Post by mbseeking on Nov 12, 2015 1:51:35 GMT -5
Either party will have rights to terminate. This is what milestones are for in contracts. I remember distinctly Matt saying they achieved the early ones related to production - so SNY could not just walk away. Well that's swung the other way time for SNY to perform.. Sure I dont have access to the precise wording of the contract , but missed milestones mean decisions can be made without further recourse.
|
|
|
|
Post by trenddiver on Nov 12, 2015 2:27:05 GMT -5
Either party will have rights to terminate. This is what milestones are for in contracts. I remember distinctly Matt saying they achieved the early ones related to production - so SNY could not just walk away. Well that's swung the other way time for SNY to perform.. Sure I dont have access to the precise wording of the contract , but missed milestones mean decisions can be made without further recourse. I suggest you take a look at Exhibit 10.1 to the 3rd quarter 2014 10-q, specifically Article 12. Your assertions are incorrect. Mannkind can terminate only if a ruling is obtained that Sanofi has failed to use Commercially Reasonable Efforts. There are no termination rights related to missed milestones. Trend |
|
